Related Experiment Video
Updated: Jun 23, 2026

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Epstein-Barr virus infection in patients with MOGAD
Giorgia T Maniscalco1,2, Alessandro Dinoto3, Maria C Foglia4
1Neurological Clinic and Stroke Unit, Multiple Sclerosis Regional Center, "A. Cardarelli" Hospital, Naples, Italy.
Background:
Epstein-Barr virus (EBV) infection increases the risk of having multiple sclerosis (MS). Data on adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are lacking.
Objective:
To compare EBV serological status in MOGAD versus MS.
Methods:
We measured antibodies to Epstein-Barr nuclear antigen (EBNA-1) and viral capsid antigen (VCA) antigens in 129 patients (MS = 74, MOGAD = 55) by chemiluminescence immunoassays.
Results:
VCA-IgG were detected in 97.3% of MS and 96.4% of MOGAD cases, while EBNA-1-IgG in 97.3% of MS and 80% of MOGAD (p = 0.001). EBNA-1 (p < 0.001) and VCA (p = 0.03) antibodies levels were higher in MS patients.
Conclusion:
EBV antibodies are higher in MS versus MOGAD, suggesting a possible different role of EBV in the pathogenesis of the two conditions.
Insights
Epstein-Barr virus (EBV) antibodies are significantly higher in multiple sclerosis (MS) patients compared to those with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), suggesting distinct roles in disease pathogenesis.
Area of Science:
- Neuroimmunology
- Virology
Background:
- Epstein-Barr virus (EBV) infection is a known risk factor for multiple sclerosis (MS).
- Limited data exist regarding EBV serological status in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Purpose of the Study:
- To compare Epstein-Barr virus (EBV) serological status between patients with MOGAD and MS.
Main Methods:
- Antibodies to EBV antigens (EBNA-1 and VCA) were quantified using chemiluminescence immunoassays.
- The study included 129 patients: 74 with MS and 55 with MOGAD.
Main Results:
- High prevalence of VCA-IgG antibodies in both MS (97.3%) and MOGAD (96.4%) cohorts.
- Significantly lower detection rates of EBNA-1-IgG in MOGAD (80%) compared to MS (97.3%) (p = 0.001).
- Elevated levels of EBNA-1-IgG (p < 0.001) and VCA-IgG (p = 0.03) antibodies were observed in MS patients versus MOGAD patients.
Conclusions:
- EBV antibody levels differ between MS and MOGAD.
- These findings suggest a potentially distinct role for EBV in the pathogenesis of MS and MOGAD.
Related Concept Videos
Bacterial Meningitis
Arboviral Encephalitis
Cytomegalovirus Disease
Cryptococcal Meningitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology

